Deciphering how the GR forms oligomers—through the binding of several subunits—opens a crucial avenue for developing more ...
The gastroparesis market is poised for significant growth, driven by the emergence of novel therapeutic classes such as the Dopamine D2 receptor antagonist (GIMOTI). Meanwhile, novel therapies like ...